Zenas BioPharma Statistics
Total Valuation
Zenas BioPharma has a market cap or net worth of $1.95 billion. The enterprise value is $1.63 billion.
Important Dates
The last earnings date was Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zenas BioPharma has 53.68 million shares outstanding. The number of shares has increased by 1,252.33% in one year.
| Current Share Class | 53.68M |
| Shares Outstanding | 53.68M |
| Shares Change (YoY) | +1,252.33% |
| Shares Change (QoQ) | +0.70% |
| Owned by Insiders (%) | 1.26% |
| Owned by Institutions (%) | 52.17% |
| Float | 31.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 100.32 |
| Forward PS | n/a |
| PB Ratio | 7.71 |
| P/TBV Ratio | 9.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 108.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.66, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.66 |
| Quick Ratio | 5.57 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -68.33% and return on invested capital (ROIC) is -43.91%.
| Return on Equity (ROE) | -68.33% |
| Return on Assets (ROA) | -33.72% |
| Return on Invested Capital (ROIC) | -43.91% |
| Return on Capital Employed (ROCE) | -72.59% |
| Revenue Per Employee | $115,385 |
| Profits Per Employee | -$1.46M |
| Employee Count | 130 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zenas BioPharma has paid $244,000 in taxes.
| Income Tax | 244,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +118.41% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +118.41% |
| 50-Day Moving Average | 25.92 |
| 200-Day Moving Average | 14.71 |
| Relative Strength Index (RSI) | 69.47 |
| Average Volume (20 Days) | 575,440 |
Short Selling Information
The latest short interest is 4.77 million, so 8.88% of the outstanding shares have been sold short.
| Short Interest | 4.77M |
| Short Previous Month | 4.34M |
| Short % of Shares Out | 8.88% |
| Short % of Float | 14.99% |
| Short Ratio (days to cover) | 8.22 |
Income Statement
In the last 12 months, Zenas BioPharma had revenue of $15.00 million and -$189.90 million in losses. Loss per share was -$4.53.
| Revenue | 15.00M |
| Gross Profit | -146.50M |
| Operating Income | -195.70M |
| Pretax Income | -189.66M |
| Net Income | -189.90M |
| EBITDA | -195.62M |
| EBIT | -195.70M |
| Loss Per Share | -$4.53 |
Full Income StatementBalance Sheet
The company has $290.88 million in cash and $798,000 in debt, giving a net cash position of $290.09 million or $5.40 per share.
| Cash & Cash Equivalents | 290.88M |
| Total Debt | 798,000 |
| Net Cash | 290.09M |
| Net Cash Per Share | $5.40 |
| Equity (Book Value) | 196.43M |
| Book Value Per Share | 4.65 |
| Working Capital | 244.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$158.47 million and capital expenditures -$92,000, giving a free cash flow of -$158.57 million.
| Operating Cash Flow | -158.47M |
| Capital Expenditures | -92,000 |
| Free Cash Flow | -158.57M |
| FCF Per Share | -$2.95 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,304.64% |
| Pretax Margin | -1,264.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zenas BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,252.33% |
| Shareholder Yield | -1,252.33% |
| Earnings Yield | -9.87% |
| FCF Yield | -8.24% |
Dividend DetailsAnalyst Forecast
The average price target for Zenas BioPharma is $37.86, which is 4.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $37.86 |
| Price Target Difference | 4.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 124.17% |
| EPS Growth Forecast (5Y) | -25.70% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zenas BioPharma has an Altman Z-Score of -0.86 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.86 |
| Piotroski F-Score | 1 |
